Pharma Mirror

NOVEMBER 21, 2020

Medisafe, a leading digital therapeutics company specializing in digital companions, has been selected by UCB to develop branded digital drug companions for its antiepileptic medications, with greater capabilities to expand across additional brands. million patients in the US who live with the neurological condition.

Development 130

Development Branding Doctors Doctor 130

pharmaphorum

MARCH 1, 2024

Gain insights into the research and development strategies of leading companies like Alexion, Samsung Biologics, JPM, UCB, and Clinigen with in-depth interviews and analysis for 2024.

Development 52

Development Research 52

Fierce Pharma

JUNE 26, 2023

. | Lundbeck CEO Deborah Dunsire is retiring on a high note in the neuroscience company’s history. After hitting the company's highest quarterly revenue in the first quarter, the five-year Lundbeck chief executive will pass the baton to UCB's neurology head.

Sales 110

Sales 110

pharmaphorum

FEBRUARY 26, 2021

UCB and Microsoft have announced a multi-year strategic collaboration to advance the digitalisation of the Belgian pharma company and accelerate its research efforts. The companies have already been working together on the COVID Moonshot Project, which aimed to create an orally available antiviral to combat the SARS-CoV-2 coronavirus.

Drugs 95

Drugs Medicine Pharma Companies Clinical Development 95

BioSpace

DECEMBER 1, 2021

Novartis held an investor event to discuss their research programs, highlighting its partnership with Belgian pharma company UCB worth up to $1.5

Pharma Companies 79

Pharma Companies Research 79

Drug Discovery World

JANUARY 4, 2024

2023 was a pivotal year for the company from a strategic perspective, including a €22.75 million Series A extension in April 2023, a strategic research collaboration with UCB in May 2023, and the acquisition of Theragnostics in June 2023. Ruediger talks about the future for the company and its therapeutic pipeline.

Development 64

Development Drugs Production Research 64

Drug Discovery World

MARCH 5, 2024

Stefanie Dedeurwaerdere is Global Strategy Lead for Pipeline Development in Global Epilepsy & Rare Syndromes at UCB. LR: What is UCB’s current focus on research in this area and are you able to outline any of your drug discovery programmes?

Genetics 59

Genetics Research Scientist Development 59

Drug Discovery World

FEBRUARY 16, 2024

UCB has revealed new data demonstrating a 55% improvement in adults with moderate to severe hidradenitis suppurativa (HS) treated with monoclonal antibody bimekizumab. The data were presented at the 13th Conference of the European Hidradenitis Suppurativa Foundation (EHSF) in Lyon, France (7-9 February).

Antibody 52

Antibody Dermatology Drugs Clinical Trials 52

BioTech 365

MAY 25, 2021

Iktos Announce Collaboration with UCB in AI for Retrosynthesis Iktos Announce Collaboration with UCB in AI for Retrosynthesis PARIS–(BUSINESS WIRE)–Iktos, a company specialized in Artificial Intelligence for new drug design and UCB, a global biopharma company focusing on neurology and … Continue reading →

Drugs 40

Drugs 40

Drug Discovery World

JANUARY 4, 2024

2023 was a pivotal year for the company from a strategic perspective, including a €22.75 million Series A extension in April 2023, a strategic research collaboration with UCB in May 2023, and the acquisition of Theragnostics in June 2023. Ruediger talks about the future for the company and its therapeutic pipeline.

Drugs 59

Drugs Development Production Research 59

Drug Channels

OCTOBER 4, 2023

This year’s review includes the following 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below. However, some companies had net price gains. See the second chart below.

Branding 84

Branding Drugs Manufacturing 84

pharmaphorum

DECEMBER 2, 2021

Novartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first oral, disease-modifying drug for the disease – if it can avoid the fate of earlier drugs in the class. The post Novartis takes aim at risky Parkinson’s target with $1.5bn UCB deal appeared first on.

Antibody 109

Antibody Licensing Licensing Gene Therapy 109

pharmaphorum

MAY 18, 2022

One research-driven company with a strong patient focus in neurology is UCB. “In says Charl van Zyl, UCB’s executive vice president neurology & head of Europe & International Markets. Over the next decade, UCB plans to continue its strong growth both in neurology and immunology.

Gene Therapy 92

Gene Therapy Gene Genetics Development 92

pharmaphorum

MAY 13, 2022

The FDA has delivered a blow to UCB’s late-stage pipeline, after saying it is unable to approve its latecomer IL-17 inhibitor bimekizumab for moderate-to-severe plaque psoriasis. The delay to approval means that UCB is reviewing its financial forecasts for 2022, although it hasn’t yet determined what the impact will be.

Sales 52

Sales Marketing Drugs Regulation 52

pharmaphorum

DECEMBER 14, 2022

Pharma consultancy United BioSource, or UBC (not to be confused with pharma company UCB), has promoted former chief operating officer Bekki Brown to the role of president and CEO, effective January 1. Life sciences commercialisation company Indegene has appointed Georgia Papathomas as non-executive independent director to the board.

Life Science 98

Life Science Gene Therapy Gene Editing Gene 98

Drug Channels

JUNE 13, 2023

This year’s review includes the following 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below. However, some companies had net price gains. See the second chart below.

Branding 78

Branding Drugs Manufacturing 78

Drug Discovery World

FEBRUARY 16, 2024

The company originates from the aggregation of six Medicxi companies. Monoclonal antibody improves severe hidradenitis suppurativa by 55% UCB has revealed new data demonstrating a 55% improvement in adults with moderate to severe hidradenitis suppurativa (HS) treated with monoclonal antibody bimekizumab.

Dermatology 52

Dermatology Drugs Gene Expression Antibody 52

Drug Channels

MAY 10, 2022

This year’s review includes 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers.

Branding 89

Branding Drugs Manufacturing 89

Pharmaceutical Technology

MAY 8, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Antibody 130

Antibody Medicine Production DNA 130

pharmaphorum

FEBRUARY 4, 2022

Belgian drugmaker UCB says it will be able to file not one but two new drug therapies for autoimmune disease generalised myasthenia gravis (gMG) this year, after its C5 inhibitor zilucoplan hit the mark in a phase 3 trial. UCB acquired rights to the drug when it bought US biotech Ra Pharma in a deal worth around $2.1

Sales 52

Sales Antibody FDA Approval Drugs 52

Pharmaceutical Technology

MAY 15, 2023

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.

Antibody 130

Antibody DNA Development Vaccination 130

Drug Channels

JULY 28, 2022

This year’s review includes 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers.

Branding 87

Branding Drugs Manufacturing 87

pharmaphorum

APRIL 26, 2021

The partnership will be based on Jolly Good’s technology and Teijin’s strategic expertise, the companies said. Jolly Good is a medical technology company that develops VR solutions and AI-based medical and welfare services that analyse user behaviour in the VR space.

Development 120

Development Medicine Production Marketing 120

pharmaphorum

APRIL 21, 2022

One of the things UCB hopes its new framework will do is enable its teams to capture and share data-driven patient insights that will, in turn, inform the development of products that tackle unmet need. “The Every UCB colleague was doing it their own way, so the approach was fragmented. Outcome measures. Cohesive approach.

Production 98

Production Development Research Manufacturing 98

Pharmaceutical Technology

DECEMBER 19, 2022

This consists of any projects that have expanded the company’s footprint in the sector, including: contract wins; launching in new territories; launching new product lines; the acquisition and expansion of facilities and real estate; acquisition of new machinery or other assets; improved logistics; partnerships; and significant staff increases.

Production 130

Production Marketing Manufacturing Research 130

pharmaphorum

OCTOBER 13, 2022

The therapy has been on the market in Europe since 2019, which is marketed by UCB in the region, though by Amgen and Astellas in other areas. UCB recently revealed that a study had been carried out using 3D modelling to visualise and assess on-going treatment for osteoporosis.

Marketing 98

Marketing Antibody Research Clinical Trials 98

XTalks

JULY 10, 2023

Euronext Brussels (UCB), a biopharma company headquartered in Brussels, Belgium, recently announced that the US Food and Drug Administration (FDA) has granted approval for its drug, Rystiggo (rozanolixizumab), for the treatment of generalized myasthenia gravis (gMG).

FDA Approval 98

FDA Approval Antibody Protein Engineer 98

The Pharma Data

MARCH 1, 2022

Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. SRIW (Société Régionale d’Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures.

Protein 52

Protein Licensing Licensing Development 52

Drug Discovery World

MARCH 22, 2023

Aitia and UCB focus on drug targets for Huntington’s Disease UCB and Aitia have agreed a collaboration focused on the discovery and validation of novel drug targets and drug candidates for Huntingdon’s disease. The post Industry collaborations advancing drug discovery appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Protein Development Licensing 52

pharmaphorum

APRIL 21, 2022

One of the leading companies in the bid to bring a new class of alpha-synuclein targeting drugs to market for Parkinson’s disease – AbbVie – is ducking out of the challenge. ” She added that BioArctic will now “investigate options to continue the development of this asset.”

Antibody 97

Antibody Protein Gene Therapy Pharma Companies 97

Pharmaceutical Technology

DECEMBER 22, 2022

The programme provides a platform to recognise the people and companies that are driving change. Our programme is designed to highlight excellence within the sector by looking at a range of corporate activities including deals, business projects and company initiatives, both internal and in the community. Business Expansion.

Insulin 130

Insulin Production Development Genetics 130

Drug Discovery World

JULY 19, 2023

I am the Chief Medical Officer at Ariceum Therapeutics, a private company focused on developing novel targeted radiopharmaceuticals for the treatment of cancer. Balancing involvement and delegation is key for the success of the project, the department, and eventually the company. What’s been the highlight of your career so far?

Research 52

Research Development Production Clinical Development 52

pharmaphorum

OCTOBER 31, 2022

The decision to drop the oral ROR gamma inverse agonist – also known as ABBV-157 – came after analysis of a recently concluded nonclinical toxicology study, according to an Inventiva statement, in which the company said it does not expect the move to have any impact on its cash position.

Drugs 52

Drugs Production Development Trials 52

Delveinsight

OCTOBER 1, 2021

There are several therapies in the market to address the Myasthenia Gravis burden, and many companies are still working on their drug candidates to cope with Myasthenia Gravis. The company is generating a tremendous amount of revenue every year from the Soliris drug. The company made a profit of USD 3144.1

Marketing 85

Marketing Antibody Drugs Sales 85

pharmaphorum

SEPTEMBER 20, 2022

The company recorded sales of $3.25 Amgen company is seeking to defend its osteoporosis franchise with UCB-partnered Evenity (romosozumab), an anti-sclerostin antibody that was approved for postmenopausal osteoporosis in 2019 and brought in $530 million last year – a rise of more than 50%.

Branding 52

Branding Medicine Marketing Sales 52

pharmaphorum

SEPTEMBER 8, 2022

DiME hopes nocturnal scratch will offer pharmaceutical companies “the tools needed to de-risk the selection” of the endpoint. As yet, no new medical product has been approved on the basis of a digital endpoint.

Dermatology 52

Dermatology Production Radiology Development 52

pharmaphorum

NOVEMBER 14, 2022

The cash injection from the UK and Singapore-based biotech’s existing shareholders adds to $64 million raised in 2021 via an earlier rights issue, and comes a couple of weeks before the company is due to present its LUCIDITY data on full at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco on 30 November.

Drugs 52

Drugs Protein Clinical Trials Clinical Trials 52